Purpose: To investigate the frequency of discordance and to identify factors associated with discordance between ultrasonographic and elastographic grades for assessing hepatic fibrosis in Asian patients with chronic hepatitis B.
Methods: Three hundred thirty-four patients with chronic hepatitis B for which both conventional ultrasonography and liver stiffness measurements using elastography were available were included. Patients were graded as 'normal', 'chronic liver disease', or 'liver cirrhosis' by ultrasonography, and as 'no significant fibrosis', 'significant fibrosis', or 'liver cirrhosis' by elastography, and the results of these two modalities were compared. Logistic regression analyses were performed to identify independent factors associated with discordant results.
Results: Of the 334 patients, 153 (45.8 %), 115 (34.4 %), and 66 (19.8 %) patients were 'normal', 'chronic liver disease', and 'liver cirrhosis', respectively, based on the ultrasonographic grades, and 290 (86.8 %), 29 (8.7 %), and 15 (4.5 %) patients were 'no significant fibrosis,' 'significant fibrosis', and 'liver cirrhosis', respectively, based on the elastographic values. Among them, 173 (51.8 %) showed discordance with respect to severity of hepatic fibrosis. In multivariable analysis, discordance was more frequent in patients with ultrasonographic grades of 'chronic liver disease' [adjusted odds ratio (AOR), 1924; P < 0.001] and 'liver cirrhosis' (AOR, 4498; P < 0.001), whereas patients with an elastographic grade of 'liver cirrhosis' showed a negative association with discordance (AOR, 0.002; P = 0.007).
Conclusion: There was a high rate of discordance between hepatic fibrosis grades determined by ultrasonography and elastography. Considering the accuracy of liver stiffness evaluation by elastography, conventional ultrasonography might overestimate hepatic fibrosis in chronic hepatitis B.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10396-015-0684-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world analysis of acamprosate use in patients with cirrhosis and alcohol-associated hepatitis.
BMJ Open Gastroenterol
December 2024
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Objective: Preventing return to alcohol is of critical importance for patients with alcohol-related cirrhosis and/or alcohol-associated hepatitis. Acamprosate is a widely used treatment for alcohol use disorder (AUD). We assessed the impact of acamprosate prescription in patients with advanced liver disease on abstinence rates and clinical outcomes.
View Article and Find Full Text PDFParallel randomised trial testing community fibrosis assessment for suspected non-alcoholic fatty liver disease: outcomes from LOCATE-NAFLD.
BMJ Open Gastroenterol
December 2024
Australian Centre for Health Services Innovation, Centre for Healthcare Transformation, School of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Kelvin Grove, Queensland, Australia
Objective: Non-alcoholic fatty liver disease (NAFLD) is estimated to affect a third of Australian adults, and its prevalence is predicted to rise, increasing the burden on the healthcare system. The LOCal Assessment and Triage Evaluation of Non-Alcoholic Fatty Liver Disease (LOCATE-NAFLD) trialled a community-based fibrosis assessment service using FibroScan to reduce the time to diagnosis of high-risk NAFLD and improve patient outcomes.
Methods: We conducted a 1:1 parallel randomised trial to compare two alternative models of care for NAFLD diagnosis and assessment.
Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017-2023.
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Our study investigated the prevalence of lean steatotic liver disease (SLD) and its subcategories, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-related and alcohol-related SLD (MetALD), and alcohol-related liver disease (ALD) among lean adults in the US. Analysing data from 2965 lean adults (≥ 18 years) from the National Health and Nutrition Examination Survey (2017-2023), we found the age-adjusted prevalence of lean SLD to be 12.8%.
View Article and Find Full Text PDFThe Impact of Hepatic Hydrothorax on the Outcome of Liver Cirrhosis: A Comparative Study.
J Clin Med
January 2025
Department of Nuclear Medicine, University of Medicine and Pharmacy Carol Davila Bucharest Romania, 020021 Bucharest, Romania.
Hepatic hydrothorax (HH) is a severe cirrhosis complication requiring early diagnosis and appropriate management. This study aimed to assess the impact of HH on the disease severity and mortality of cirrhotic patients and compare their clinical and biological profiles with those of patients without HH. This retrospective study involved 155 patients diagnosed with cirrhosis, of whom 31 had HH.
View Article and Find Full Text PDFIntegrating Muscle Depletion with Barcelona Clinic Liver Cancer Staging to Predict Overall Survival in Hepatocellular Carcinoma.
Cancers (Basel)
December 2024
Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi 62247, Taiwan.
Background: Muscle depletion (MD) is a critical factor that influences clinical outcomes in patients with hepatocellular carcinoma (HCC). Although its role in cancer prognosis is recognized, its integration into widely used prognostic systems remains underexplored. This study aimed to evaluate the prognostic impact of MD on overall survival (OS) in HCC patients and to improve existing noninvasive prognostic models by incorporating MD-related metrics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!